Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease
Mark Sampson, Nuno Faria, Jonathan J Powell, PEACH study investigators, Mark Sampson, Nuno Faria, Jonathan J Powell, PEACH study investigators
Abstract
Background: Hyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders.
Methods: In this double-blind, parallel-group, placebo-controlled, dose-ranging study (ClinicalTrials.gov identifier NCT02151643), the efficacy and safety of 28 days of oral PT20 treatment were evaluated in patients with dialysis-dependent CKD. Participants were randomly assigned in an 8:8:8:13:13 ratio to receive PT20 (400, 800, 1600 or 3200 mg) or placebo three times daily.
Results: Among 153 participants, 129 completed treatment [7 discontinued because of adverse events (AEs), 2 because of hyperphosphataemia and 15 for other reasons]. PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration. There were no statistically significant effects of PT20 treatment on changes in haemoglobin or ferritin concentrations or transferrin saturation between Days 1 and 29. The incidence of treatment-emergent AEs was broadly similar across the PT20 and placebo groups (42-59% versus 44%). The most common PT20 treatment-related AEs were gastrointestinal, primarily diarrhoea (13-18%) and discoloured faeces (3-23%). No serious AEs were considered to be related to study treatment. There were no clinically significant changes in laboratory results reflecting acid/base status or increases in ferritin that could indicate the absorption of components of PT20.
Conclusions: In this first study investigating the efficacy and safety of PT20 in patients with hyperphosphataemia and dialysis-dependent CKD, PT20 significantly lowered serum phosphate concentrations and was generally well tolerated.
Keywords: PT20; chronic kidney disease; ferric oxide; hyperphosphataemia; phosphate binder.
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Figures
References
- Block GA, Hulbert-Shearon TE, Levin NW. et al.. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617
- Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Semin Dial 2007; 20: 286–294
- Port FK, Pisoni RL, Bommer J. et al.. Improving outcomes for dialysis patients in the International Dialysis Outcomes and Practice Patterns study. Clin J Am Soc Nephrol 2006; 1: 246–255
- National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–S201
- Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1–59
- Tonelli M, Pannu N, Manns B.. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312–1324
- Locatelli F, Del Vecchio L, Violo L. et al.. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf 2014; 13: 551–561
- Wu-Wong JR, Mizobuchi M.. Is there a need for new phosphate binders to treat phosphate imbalance associated with chronic kidney disease? Expert Opin Invest Drugs 2014; 23: 1465–1475
- Spasovski GB, Sikole A, Gelev S. et al.. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21: 2217–2224
- Hergesell O, Ritz E.. Phosphate binders on iron basis: a new perspective? Kidney Int 1999; 56: S42–S45
- Fresenius Medical Care North America. VELPHORO: Sucroferric Oxyhydroxide Tablet, Chewable. Prescribing information. US Food and Drug Administration.
- Keryx Biopharmaceuticals, Inc. AURYXIA: Ferric Citrate Tablet, Coated. Prescribing information. US Food and Drug Administration.
- Pai AB, Jang SM, Wegrzyn N.. Iron-based phosphate binders—a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol 2016; 12: 115–127
- Floege J, Covic AC, Ketteler M. et al.. Efficacy and safety of a novel iron-based phosphate binder in dialysis patients, in a phase III study. Kidney Int 2014; 86: 638–647
- Floege J, Covic AC, Ketteler M. et al.. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 2015; 30: 1037–1046
- Floege J, Covic AC, Ketteler M. et al.. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant 2017; 32: 1918–1926
- Wu MY, Chen YC, Lin CH. et al.. Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease. Oncotarget 2017; 8: 107283–107294
- St Peter WL, Wazny LD, Weinhandl E. et al.. A review of phosphate binders in chronic kidney disease: incremental progress or just higher costs? Drugs 2017; 77: 1155–1186
- Powell JJ, Faria NJR, Medical Research Council. Phosphate Binding and Their Uses. World patent WO/2010/015827. February 2010
- . Study to Evaluate the Efficacy and Safety of PT20 in Subjects with Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease. (8 December 2019, date last accessed)
- FOOD-INFO. E355 Adipic Acid. (8 December 2019, date last accessed)
- US Food and Drug Administration. GRAS Substances (SCOGS) Database. (8 December 2019, date last accessed)
- Kennedy GL Jr. Toxicity of adipic acid. Drug Chem Toxicol 2002; 25: 191–202
- Svedlund J, SjöDin I, Dotevall G.. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Digest Dis Sci 1988; 33: 129–134
- Kulich KR, Madisch A, Pacini F. et al.. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes 2008; 6: 12.
- McIntyre CW, Pai P, Warwick G. et al.. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 401–409
- Wüthrich RP, Chonchol M, Covic A. et al.. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 280–289
- Huml AM, Sullivan CM, Leon JB. et al.. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Ren Fail 2012; 34: 1258–1263
- Block GA, Wheeler DC, Persky MS. et al.. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407–1415
- Bommer J, Ritz E.. Hypothesis: calcium carbonate as phosphate binder—the fallacy of relying on serum phosphorus. Nephrol Dial Transplant 2010; 25: 1703–1705
- Murtagh FE, Addington-Hall J, Higginson IJ.. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82–99
- Dwyer JP, Sika M, Schulman G. et al.. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013; 61: 759–766
- Sinsakul M, Sika M, Koury M. et al.. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012; 121: c25–c29
- Geisser P, Philipp E.. PA21: a novel phosphate binder for the treatment of in kidney disease. Clin Nephrol 2010; 74: 4–11
- Rhee EP, Souza A, Farrell L. et al.. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010; 21: 1041–1051
- Niwa T, Ohki T, Maeda K. et al.. Pattern of aliphatic dicarboxylic acids in uremic serum including a new organic acid, 2,4-dimethyladipic acid. Clin Chim Acta 1979; 99: 71–83
Source: PubMed